Skip to content

US · PRQR · BIOTECHNOLOGY

ProQR Therapeutics N.V. (PRQR) intrinsic value and stock valuation

$1.04as of 2026-11-21 · Mkt cap 207.46M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

ProQR Therapeutics N.V. DCF and intrinsic value

InvestorsCraft values PRQR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PRQR’s statements →

ProQR Therapeutics N.V. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Leiden, ZH 2333 Ck proqr.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$15.3M+71.5% 5y CAGRd
20132025
Net income
-$-40.52M
20132025
Free cash flow
-$-51.69M
20132025
Total equity
$49.4M-6.5% 5y CAGRd
20122025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$15.3M$18.9M$6.51M$3.59M$1.33M
Operating income-$-42.15M-$-30.47M-$-31.86M-$-65.16M-$-57.21M
Net income-$-40.52M-$-27.76M-$-28.12M-$-64.42M-$-60.74M
EPSd-$-384.7K-$-339.9K-$-347.12K-$-899.22K-$-946.4K
Operating cash flow-$-50.71M-$-36.39M$21.6M-$-68.51M-$-26.01M
Capital expenditure-$-980K-$-1.42M-$-1.37M-$-710K-$-480K
Free cash flow-$-51.69M-$-37.81M$20.2M-$-69.22M-$-26.5M
Total assets$112.7M$168M$152.3M$171.3M$209.6M
Total debt$14M$17.2M$21.8M$22M$60.4M
Net debt-$-78.39M-$-132.19M-$-109.57M-$-72.8M-$-127.15M
Total equity$49.4M$88.6M$45.7M$66.7M$113.2M
Cash and short-term investments$92.4M$149.4M$131.4M$94.8M$187.5M
Income statement
20252024202320222021
Revenue$15.3M$18.9M$6.51M$3.59M$1.33M
Cost of revenue$2.6M$0.00$0.00$0.00$0.00
Gross profit$12.7M$18.9M$6.51M$3.59M$1.33M
Research and development expenses$40.7M$36.4M$25.2M$50.9M$42.2M
Selling, general and administrative expenses$15.1M$13.7M$16.2M$18.7M$17.4M
Other expenses-$-940K-$-640K-$-3.01M-$-770K-$-1.04M
Operating expenses$54.8M$49.4M$38.4M$68.8M$58.6M
Cost and expenses$57.4M$49.4M$38.4M$68.8M$58.6M
Interest income$2.24M$3.25M$2.59M$110K$10K
Interest expense$870K$1.08M$1.2M$5.13M$3.4M
Depreciation and amortization$2.6M$2.76M$2.51M$2.52M$2.33M
Ebitda-$-37.04M-$-24.12M-$-24.1M-$-56.46M-$-54.95M
Operating income-$-42.15M-$-30.47M-$-31.86M-$-65.16M-$-57.21M
Total other income/expenses, net$1.65M$2.51M$4.05M$1.05M-$-3.47M
Income before tax-$-40.5M-$-27.96M-$-27.81M-$-64.11M-$-60.68M
Income tax expense$20K-$-200K-$-80K$100K$120K
Net income-$-40.52M-$-27.76M-$-28.12M-$-64.42M-$-60.74M
Weighted average shares outstanding$105.3M$81.7M$81M$71.6M$64.2M
Weighted average diluted shares outstanding$105.3M$81.7M$81M$71.6M$64.2M
Balance sheet
20252024202320222021
Cash and short-term investments$92.4M$149.4M$131.4M$94.8M$187.5M
Net receivables$5.08M$2.03M$1.4M$56.3M$820K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$100.1M$153.8M$133.7M$154.5M$191.5M
Property, plant and equipment, net$12.6M$14.1M$18.7M$16.2M$17.5M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$620K$630K
Total non-current assets$12.6M$14.1M$18.7M$16.9M$18.1M
Total assets$112.7M$168M$152.3M$171.3M$209.6M
Accounts payable$300K$20K$1.7M$390K$190K
Short-term debt$4.44M$6.15M$1.78M$3.89M$6.3M
Deferred revenue$17.5M$0.00$22.7M$0.00$0.00
Total current liabilities$32.4M$38.9M$37.8M$21M$27.6M
Long-term debt$9.54M$11.1M$20M$18.1M$54.1M
Deferred revenue, non-current$21.4M$0.00$48.8M$0.00$0.00
Total non-current liabilities$30.9M$40.5M$68.8M$83.7M$68.8M
Capital lease obligations$9.54M$12.6M$15.3M$15.2M$16.3M
Total liabilities$63.4M$79.4M$106.6M$104.6M$96.4M
Common stock$4.31M$4.31M$3.72M$3.37M$3M
Retained earnings-$-467.31M-$-427.16M-$-442.8M-$-379.11M-$-317.77M
Accumulated other comprehensive income (loss)$28.7M$27.6M$28.7M$30.3M$30.3M
Total equity$49.4M$88.6M$45.7M$66.7M$113.2M
Total investments$0.00$0.00$0.00$620K$630K
Total debt$14M$17.2M$21.8M$22M$60.4M
Net debt-$-78.39M-$-132.19M-$-109.57M-$-72.8M-$-127.15M
Cash flow statement
20252024202320222021
Net income-$-40.52M-$-27.76M-$-27.73M-$-64.2M-$-60.8M
Depreciation and amortization$2.6M$2.76M$2.51M$2.52M$2.33M
Stock-based compensation$0.00$2.54M$3.11M$2.87M$6.22M
Change in working capital-$-16.73M-$-13.26M$49M-$-4.99M$25M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-50.71M-$-36.39M$21.6M-$-68.51M-$-26.01M
Investments in property, plant and equipment-$-980K-$-1.42M-$-1.37M-$-710K-$-480K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-980K-$-4.07M$4.28M-$-700K-$-420K
Common stock issued$70K$71.6M$0.00$14.1M$108.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-1.76M$70.3M-$-2.27M-$-30.89M$136.8M
Net change in cash-$-39.3M$30.5M$24.2M-$-92.75M$111.7M
Cash at end of period$92.4M$149.4M$118.9M$94.8M$187.5M
Operating cash flow-$-50.71M-$-36.39M$21.6M-$-68.51M-$-26.01M
Capital expenditure-$-980K-$-1.42M-$-1.37M-$-710K-$-480K
Free cash flow-$-51.69M-$-37.81M$20.2M-$-69.22M-$-26.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About ProQR Therapeutics N.V.

        ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.

        CEO
        Daniel Anton de Boer
        Employees
        166
        Beta
        0.03

        Explore

        Frequently asked questions

        What is the intrinsic value of ProQR Therapeutics N.V. (PRQR)?

        InvestorsCraft does not currently publish an intrinsic value for PRQR. How the IC value is calculated.

        Is PRQR undervalued?

        InvestorsCraft does not publish an undervaluation signal for PRQR at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.